➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
AstraZeneca
Moodys
McKinsey
Dow

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Simtuzumab


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Simtuzumab?

Simtuzumab is an investigational drug.

There have been 6 clinical trials for Simtuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Fibrosis, Adenocarcinoma, and Pulmonary Fibrosis. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].

There are twelve US patents protecting this investigational drug and two hundred and twenty-two international patents.

Recent Clinical Trials for Simtuzumab
TitleSponsorPhase
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3Gilead SciencesPhase 2
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)Gilead SciencesPhase 2
Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF)Gilead SciencesPhase 2

See all Simtuzumab clinical trials

Clinical Trial Summary for Simtuzumab

Top disease conditions for Simtuzumab
Top clinical trial sponsors for Simtuzumab

See all Simtuzumab clinical trials

US Patents for Simtuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Simtuzumab   Start Trial Compositions comprising oxo-derivatives of fatty acids and methods of making and using same DS BIOPHARMA LIMITED (Dublin, IE)   Start Trial
Simtuzumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Simtuzumab   Start Trial Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same Afimmune Limited (IE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.